Ding Li1,2,3, Jianqiu Xu1,2,3, Xiaochen Dong1,2,3, Wenjing Chen1,2,3, Lingling Pan1,2,3, Hao Jiang1,2,3, Jingye Pan1,2,3, Yueyue Huang1,2,3. 1. Department of Intensive Care Unit, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. 2. Key Laboratory of Intelligent Treatment and Life Support for Critical Diseases of Zhejiang Provincial, Wenzhou, China. 3. Wenzhou Key Laboratory of Critical Care and Artificial Intelligence, Wenzhou, China.
Abstract
BACKGROUNDS: Globally, the high morbidity and mortality of gastric carcinoma (GC) have been one of the great challenges facing humanity. However, the early diagnosis of GC is still unknown. Matrilin-3 (MATN3) is a member of the extracellular matrix (ECM) protein family. Previous studies have reported a correlation between the expression of MATN3 and bone disease. However, the role of MATN3 in GC has not been reported in depth, which can have a possible far-reaching implication for GC. METHODS: We explored the diagnostic and prognostic value and pathway enrichment of MATN3 expression in GC. Limma package conducted by R was used to analysis the difference expression data of MATN3 from The Cancer Genome Atlas (TCGA). The receiver operating characteristic (ROC) curve analysis was used to estimate the diagnostic value of MATN3 expression. univariate and multivariate analysis were used to assess the prognostic value of MATN3, and gene set enrichment analysis (GSEA) to identify the enriched signaling pathways. RESULTS: MATN3 was found to be significantly higher in GC tissue samples. GC patients with high MATN3 expression had poor prognosis. Then, GSEA showed that the gene sets were correlated with signaling pathways including ECM receptor interaction, hypertrophic cardiomyopathy (HCM), and glycosaminoglycan biosynthesis chondroitin sulfate, among others. CONCLUSIONS: The study suggests that MATN3 can serve as a potential diagnostic and prognostic biomarker for GC. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
BACKGROUNDS: Globally, the high morbidity and mortality of gastric carcinoma (GC) have been one of the great challenges facing humanity. However, the early diagnosis of GC is still unknown. Matrilin-3 (MATN3) is a member of the extracellular matrix (ECM) protein family. Previous studies have reported a correlation between the expression of MATN3 and bone disease. However, the role of MATN3 in GC has not been reported in depth, which can have a possible far-reaching implication for GC. METHODS: We explored the diagnostic and prognostic value and pathway enrichment of MATN3 expression in GC. Limma package conducted by R was used to analysis the difference expression data of MATN3 from The Cancer Genome Atlas (TCGA). The receiver operating characteristic (ROC) curve analysis was used to estimate the diagnostic value of MATN3 expression. univariate and multivariate analysis were used to assess the prognostic value of MATN3, and gene set enrichment analysis (GSEA) to identify the enriched signaling pathways. RESULTS: MATN3 was found to be significantly higher in GC tissue samples. GC patients with high MATN3 expression had poor prognosis. Then, GSEA showed that the gene sets were correlated with signaling pathways including ECM receptor interaction, hypertrophic cardiomyopathy (HCM), and glycosaminoglycan biosynthesis chondroitin sulfate, among others. CONCLUSIONS: The study suggests that MATN3 can serve as a potential diagnostic and prognostic biomarker for GC. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
Authors: M Juhani Junttila; Lauri Holmström; Katri Pylkäs; Tuomo Mantere; Kari Kaikkonen; Katja Porvari; Marja-Leena Kortelainen; Lasse Pakanen; Risto Kerkelä; Robert J Myerburg; Heikki V Huikuri Journal: Circulation Date: 2018-06-19 Impact factor: 29.690
Authors: Vamsi K Mootha; Cecilia M Lindgren; Karl-Fredrik Eriksson; Aravind Subramanian; Smita Sihag; Joseph Lehar; Pere Puigserver; Emma Carlsson; Martin Ridderstråle; Esa Laurila; Nicholas Houstis; Mark J Daly; Nick Patterson; Jill P Mesirov; Todd R Golub; Pablo Tamayo; Bruce Spiegelman; Eric S Lander; Joel N Hirschhorn; David Altshuler; Leif C Groop Journal: Nat Genet Date: 2003-07 Impact factor: 38.330